- Home
- CBNA vs DRTS Comparison
CBNA vs DRTS Comparison
Compare CBNA & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBNA
- DRTS
- Stock Information
- Founded
- CBNA 2006
- DRTS 2015
- Country
- CBNA United States
- DRTS Israel
- Employees
- CBNA N/A
- DRTS N/A
- Industry
- CBNA
- DRTS Medical/Dental Instruments
- Sector
- CBNA
- DRTS Health Care
- Exchange
- CBNA NYSE
- DRTS Nasdaq
- Market Cap
- CBNA 159.8M
- DRTS 252.8M
- IPO Year
- CBNA 2024
- DRTS N/A
- Fundamental
- Price
- CBNA $26.60
- DRTS $3.25
- Analyst Decision
- CBNA Buy
- DRTS Strong Buy
- Analyst Count
- CBNA 3
- DRTS 2
- Target Price
- CBNA $29.67
- DRTS $8.00
- AVG Volume (30 Days)
- CBNA 31.8K
- DRTS 45.6K
- Earning Date
- CBNA 08-15-2025
- DRTS 08-13-2025
- Dividend Yield
- CBNA N/A
- DRTS N/A
- EPS Growth
- CBNA 60.12
- DRTS N/A
- EPS
- CBNA 4.10
- DRTS N/A
- Revenue
- CBNA $57,087,000.00
- DRTS N/A
- Revenue This Year
- CBNA N/A
- DRTS N/A
- Revenue Next Year
- CBNA $17.50
- DRTS N/A
- P/E Ratio
- CBNA $6.49
- DRTS N/A
- Revenue Growth
- CBNA 62.88
- DRTS N/A
- 52 Week Low
- CBNA $20.01
- DRTS $1.93
- 52 Week High
- CBNA $27.97
- DRTS $4.39
- Technical
- Relative Strength Index (RSI)
- CBNA N/A
- DRTS 61.94
- Support Level
- CBNA N/A
- DRTS $2.91
- Resistance Level
- CBNA N/A
- DRTS $3.20
- Average True Range (ATR)
- CBNA 0.00
- DRTS 0.15
- MACD
- CBNA 0.00
- DRTS 0.01
- Stochastic Oscillator
- CBNA 0.00
- DRTS 80.00
About CBNA CHAIN BRIDGE BANCORP INC
Chain Bridge Bancorp Inc is engaged in banking industry. It offers commercial and personal banking services, including deposits, treasury management, payments, loans, commercial lending, residential mortgage financing, consumer loans, trusts and estate administration, wealth management, and asset custody.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.